Pfizer Retained Earnings (Accumulated Deficit) 2010-2024 | PFE

Pfizer retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
  • Pfizer retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $116.596B, a 9.47% decline year-over-year.
  • Pfizer retained earnings (accumulated deficit) for 2023 were $118.353B, a 5.81% decline from 2022.
  • Pfizer retained earnings (accumulated deficit) for 2022 were $125.656B, a 21.53% increase from 2021.
  • Pfizer retained earnings (accumulated deficit) for 2021 were $103.394B, a 14.38% increase from 2020.
Pfizer Annual Retained Earnings (Accumulated Deficit)
(Millions of US $)
2023 $118,353
2022 $125,656
2021 $103,394
2020 $90,392
2019 $97,670
2018 $89,554
2017 $85,291
2016 $71,774
2015 $71,993
2014 $72,176
2013 $69,732
2012 $54,240
2011 $46,210
2010 $42,716
2009 $40,426
Pfizer Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $)
2024-06-30 $116,596
2024-03-31 $121,318
2023-12-31 $118,353
2023-09-30 $126,411
2023-06-30 $128,796
2023-03-31 $131,102
2022-12-31 $125,656
2022-09-30 $122,967
2022-06-30 $116,608
2022-03-31 $111,193
2021-12-31 $103,394
2021-09-30 $102,252
2021-06-30 $96,346
2021-03-31 $95,158
2020-12-31 $90,392
2020-09-30 $100,284
2020-06-30 $100,203
2020-03-31 $101,000
2019-12-31 $97,670
2019-09-30 $100,113
2019-06-30 $94,440
2019-03-31 $93,388
2018-12-31 $89,554
2018-09-30 $91,995
2018-06-30 $89,860
2018-03-31 $89,961
2017-12-31 $85,291
2017-09-30 $75,043
2017-06-30 $74,107
2017-03-31 $74,847
2016-12-31 $71,774
2016-09-30 $72,846
2016-06-30 $73,350
2016-03-31 $74,971
2015-12-31 $71,993
2015-09-30 $74,019
2015-06-30 $73,620
2015-03-31 $74,471
2014-12-31 $72,176
2014-09-30 $74,292
2014-06-30 $71,627
2014-03-31 $72,028
2013-12-31 $69,732
2013-09-30 $70,381
2013-06-30 $67,628
2013-03-31 $56,972
2012-12-31 $54,240
2012-09-30 $51,256
2012-06-30 $47,904
2012-03-31 $48,124
2011-12-31 $46,210
2011-09-30 $48,121
2011-06-30 $44,320
2011-03-31 $44,926
2010-12-31 $42,716
2010-09-30 $42,873
2010-06-30 $42,010
2010-03-31 $42,429
2009-12-31 $40,426
2009-09-30 $54,835
2009-06-30 $51,965
2009-03-31 $51,863
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $148.702B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $790.248B 81.85
Novo Nordisk (NVO) Denmark $489.545B 35.30
Johnson & Johnson (JNJ) United States $373.278B 15.14
AbbVie (ABBV) United States $308.242B 16.23
Merck (MRK) United States $254.810B 16.93
Novartis AG (NVS) Switzerland $215.989B 14.36
AstraZeneca (AZN) United Kingdom $200.887B 17.90
Sanofi (SNY) $128.465B 11.64
Innoviva (INVA) United States $1.259B 10.48